203 related articles for article (PubMed ID: 10490835)
21. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
Motoyama AB; Hynes NE; Lane HA
Cancer Res; 2002 Jun; 62(11):3151-8. PubMed ID: 12036928
[TBL] [Abstract][Full Text] [Related]
22. Role of TGF alpha stimulation of the ERK, PI3 kinase and PLC gamma pathways in ovarian cancer growth and migration.
Sewell JM; Smyth JF; Langdon SP
Exp Cell Res; 2005 Mar; 304(1):305-16. PubMed ID: 15707595
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of c-erbB-2 expression an activity in human ovarian carcinoma cells by hypericin.
Hwang MS; Yum YN; Joo JH; Kim S; Lee KK; Gee SW; Kang HI; Kim OH
Anticancer Res; 2001; 21(4A):2649-55. PubMed ID: 11724334
[TBL] [Abstract][Full Text] [Related]
24. NDF/heregulin-induced cell cycle changes and apoptosis in breast tumour cells: role of PI3 kinase and p38 MAP kinase pathways.
Daly JM; Olayioye MA; Wong AM; Neve R; Lane HA; Maurer FG; Hynes NE
Oncogene; 1999 Jun; 18(23):3440-51. PubMed ID: 10376522
[TBL] [Abstract][Full Text] [Related]
25. Luteinizing hormone-induced up-regulation of ErbB-2 is insufficient stimulant of growth and invasion in ovarian cancer cells.
Warrenfeltz SW; Lott SA; Palmer TM; Gray JC; Puett D
Mol Cancer Res; 2008 Nov; 6(11):1775-85. PubMed ID: 19010824
[TBL] [Abstract][Full Text] [Related]
26. An antisense oligodeoxynucleotide that depletes RI alpha subunit of cyclic AMP-dependent protein kinase induces growth inhibition in human cancer cells.
Yokozaki H; Budillon A; Tortora G; Meissner S; Beaucage SL; Miki K; Cho-Chung YS
Cancer Res; 1993 Feb; 53(4):868-72. PubMed ID: 8428367
[TBL] [Abstract][Full Text] [Related]
27. Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors.
Creighton CJ; Hilger AM; Murthy S; Rae JM; Chinnaiyan AM; El-Ashry D
Cancer Res; 2006 Apr; 66(7):3903-11. PubMed ID: 16585219
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of EGFR-mediated phosphoinositide-3-OH kinase (PI3-K) signaling and glioblastoma phenotype by signal-regulatory proteins (SIRPs).
Wu CJ; Chen Z; Ullrich A; Greene MI; O'Rourke DM
Oncogene; 2000 Aug; 19(35):3999-4010. PubMed ID: 10962556
[TBL] [Abstract][Full Text] [Related]
29. Essential role for G proteins in prostate cancer cell growth and signaling.
Kue PF; Daaka Y
J Urol; 2000 Dec; 164(6):2162-7. PubMed ID: 11061948
[TBL] [Abstract][Full Text] [Related]
30. Experimental gene therapy of human colon cancer.
Bold RJ; Warren RE; Ishizuka J; Cho-Chung YS; Townsend CM; Thompson JC
Surgery; 1994 Aug; 116(2):189-95; discussion 195-6. PubMed ID: 8047985
[TBL] [Abstract][Full Text] [Related]
31. Blockade of the epidermal growth factor receptor tyrosine kinase activity by quercetin and luteolin leads to growth inhibition and apoptosis of pancreatic tumor cells.
Lee LT; Huang YT; Hwang JJ; Lee PP; Ke FC; Nair MP; Kanadaswam C; Lee MT
Anticancer Res; 2002; 22(3):1615-27. PubMed ID: 12168845
[TBL] [Abstract][Full Text] [Related]
32. Differential heat stress stability of epidermal growth factor receptor and erbB-2 receptor tyrosine kinase activities.
Liu SM; Carpenter G
J Cell Physiol; 1993 Nov; 157(2):237-42. PubMed ID: 7901224
[TBL] [Abstract][Full Text] [Related]
33. Sirt1 inhibitor, Sirtinol, induces senescence-like growth arrest with attenuated Ras-MAPK signaling in human cancer cells.
Ota H; Tokunaga E; Chang K; Hikasa M; Iijima K; Eto M; Kozaki K; Akishita M; Ouchi Y; Kaneki M
Oncogene; 2006 Jan; 25(2):176-85. PubMed ID: 16170353
[TBL] [Abstract][Full Text] [Related]
34. Oligonucleotide sequence-specific inhibition of gene expression, tumor growth inhibition, and modulation of cAMP signaling by an RNA-DNA hybrid antisense targeted to protein kinase A RIalpha subunit.
Nesterova M; Cho-Chung YS
Antisense Nucleic Acid Drug Dev; 2000 Dec; 10(6):423-33. PubMed ID: 11198926
[TBL] [Abstract][Full Text] [Related]
35. The oncogenic ErbB-2/ErbB-3 heterodimer is a surrogate receptor of the epidermal growth factor and betacellulin.
Pinkas-Kramarski R; Lenferink AE; Bacus SS; Lyass L; van de Poll ML; Klapper LN; Tzahar E; Sela M; van Zoelen EJ; Yarden Y
Oncogene; 1998 Mar; 16(10):1249-58. PubMed ID: 9546426
[TBL] [Abstract][Full Text] [Related]
36. Proliferative signal transduction by epidermal growth factor (EGF) in the human salivary gland adenocarcinoma (HSG) cell line.
Sato N; Kyakumoto S; Sawano K; Ota M
Biochem Mol Biol Int; 1996 Mar; 38(3):597-606. PubMed ID: 8829620
[TBL] [Abstract][Full Text] [Related]
37. Protein kinase G type Ialpha activity in human ovarian cancer cells significantly contributes to enhanced Src activation and DNA synthesis/cell proliferation.
Leung EL; Wong JC; Johlfs MG; Tsang BK; Fiscus RR
Mol Cancer Res; 2010 Apr; 8(4):578-91. PubMed ID: 20371672
[TBL] [Abstract][Full Text] [Related]
38. Type II protein kinase A up-regulation is sufficient to induce growth inhibition in SK-N-SH human neuroblastoma cells.
Kim SN; Lee GR; Hwang ES; Lee JH; Park SD; Cho-Chung YS; Hong SH
Biochem Biophys Res Commun; 1997 Mar; 232(2):469-73. PubMed ID: 9125203
[TBL] [Abstract][Full Text] [Related]
39. ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer.
Karunagaran D; Tzahar E; Beerli RR; Chen X; Graus-Porta D; Ratzkin BJ; Seger R; Hynes NE; Yarden Y
EMBO J; 1996 Jan; 15(2):254-64. PubMed ID: 8617201
[TBL] [Abstract][Full Text] [Related]
40. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling.
Graus-Porta D; Beerli RR; Daly JM; Hynes NE
EMBO J; 1997 Apr; 16(7):1647-55. PubMed ID: 9130710
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
